TOKYO -- Takeda Pharmaceutical's ambitious goal to increase sales to 5 trillion yen ($46 billion) in a decade was met with apathy from investors, underscoring the lack of returns from recent big-ticket acquisitions.
Pharmaceuticals
Takeda struggles to deliver returns from massive Shire deal
With debt load reduced, drugmaker tasked with turning acquisitions into cash flow
Takeda President Christophe Weber has said the Shire deal was made with a decade down the road in mind. (Photo by Wataru Ito)
Read Next
Latest on Pharmaceuticals
